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Indoleamine 2,3-Dioxygenase Activity Contributes to
Local Immune Suppression in the Skin Expressing
Human Papillomavirus Oncoprotein E7
Deepak Mittal1, Andrew J. Kassianos2, Lee S. Tran1, Anne-Sophie Bergot1, Christine Gosmann1,
Janin Hofmann1, Antje Blumenthal1,3, Graham R. Leggatt1 and Ian H. Frazer1
Chronic infection of anogenital epithelium with human papillomavirus (HPV) promotes development of cancer.
Many pathogens evoke immunosuppressive mechanisms to enable persistent infection. We have previously
shown that grafted skin expressing HPV16 E7 oncoprotein from a keratin-14 promoter (K14E7) is not rejected by a
syngeneic, immunocompetent host. In this study we show that indoleamine 2,3-dioxygenase (IDO) 1, an IFN-g-
inducible immunoregulatory molecule, is more highly expressed by langerin ve dermal dendritic cells (DCs)
from K14E7 skin than nontransgenic control skin. Furthermore, inhibiting IDO activity using 1-methyl-dl-
tryptophan (1-D/L-MT) promotes K14E7 skin graft rejection. Increased IDO1 expression and activity in K14E7
skin requires IFN-g and invariant natural killer T (iNKT) cells, both of which have been shown to negatively
regulate T-cell effector function and suppress K14E7 graft rejection. Furthermore, DCs from K14E7 skin express
higher levels of IFN-g receptor (IFN-gR) than DCs from control skin. K14E7 transgenic skin recruits significantly
higher numbers of DCs, independent of IFN-g and IFN-gR expression. Consistent with these observations in a
murine model, we found higher expression of IDO1 and IFN-g but not IDO2 in the cervical epithelium of patients
with HPV-associated cervical intraepithelial neoplasia (CIN) 2/3. Our data support a hypothesis that induction of
IDO1 in HPV-infected skin contributes to evasion of host immunity.
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INTRODUCTION
Human papillomavirus (HPV) is an oncogenic virus that
induces local epithelial hyperplasia. Persistent HPV infection
can eventually lead to cervical cancer development (zur
Hausen et al., 1981; Bhat et al., 2011). In most cases, tumor
immunotherapy fails in late-phase clinical trials despite
potent tumor immunity induced by immunotherapy. The
mechanisms likely to be responsible for this failure are
impaired tumor cell antigen presentation (Matsumoto et al.,
2004) and/or the generation of locally immunosuppressive
mediators that can induce tumor cell resistance to T-cell
effector mechanisms (Wang and Wang, 2007; Pardoll, 2012).
To understand the immunosuppressive mechanisms asso-
ciated with HPV infection, we developed a skin grafting
model that mimics hyperplastic precancerous lesions. Unlike
skin expressing other non-self antigens, skin expressing HPV16
E7 oncoprotein driven by the keratin 14 promoter (K14E7) fails
to reject when transplanted on a syngeneic immunocompetent
host (Dunn et al., 1997; Matsumoto et al., 2004). Resistance
of K14E7 grafts to immune-mediated rejection is mainly
dependent on IFN-g production from invariant natural killer
T (iNKT) cells (Mattarollo et al., 2010). IFN-g is a cytokine that
has both proinflammatory and anti-inflammatory functions.
Although IFN-g is often required by effector T cells for the
killing of target cells, IFN-g can also induce immune
mediators that negatively regulate effector T-cell function
(Minguela et al., 2007).
IFN-g is an inducer of indoleamine 2,3 dioxygenase 1
(IDO1), which catalyzes the first rate-limiting step of trypto-
phan metabolism and converts L-tryptophan into metabolites
called ‘‘kynurenines’’ (Munn and Mellor, 2012). Tryptophan is
an essential amino acid required for the function of effector
T cells, whereas kynurenines has multiple effects on T cells
that includes inhibition of proliferation, induction of apoptosis,
and differentiation into a regulatory phenotype (Orabona and
Grohmann, 2011). Other enzymes that are involved in
tryptophan metabolism and have a possible role in immune
resistance include tryptophan 2,3-dioxygenase (TDO)
(Platten et al., 2012) and tryptophan hydroxylase-1 (Nowak
et al., 2012). However, IDO1 is by far the most studied
immunoregulatory enzyme. In addition to classical IDO
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(IDO1), IDO2 is a recently described isoform of IDO that
explains some of the functions not previously explained by
IDO1 (Metz et al., 2007). IDO activity controls allograft
rejection, protects against autoimmune disease, and
contributes to inflammatory diseases such as rheumatoid
arthritis and colitis (reviewed in Orabona and Grohmann,
2011). IDO1 and IDO2 are expressed by a range of human
cancers (Lob et al., 2009; Godin-Ethier et al., 2011) and IDO
inhibitor 1-D-MT is in clinical trial for the treatment of solid
tumors that cannot be removed by surgery.
IDO1-deficient mice are resistant to carcinogen-induced
skin tumors (Muller et al., 2008). In preclinical research, both
small hairpin RNA–mediated (Huang et al., 2011) and
small interfering RNA–mediated (Yen et al., 2009) targeting
of IDO1 and IDO2 has been successfully used for metastatic
liver (Huang et al., 2011) and murine bladder tumor models
(Yen et al., 2009). Recently, it has been shown that the
percentage of cells expressing IL-10, Fox-P3, IFN-g, and
IDO increases from normal to cervical intraepithelial
neoplasia (CIN), suggesting a role of IFN-g-induced IDO1 in
a tumor immune escape mechanism (Kobayashi et al., 2008).
IDO1 activity in murine dendritic cells (DCs) has been
linked with immune tolerance and suppression of anti-
tumor immunity (Sharma et al., 2007; Huang et al., 2010;
Park et al., 2012).
As IDO is essential to the outcome of immune responses
against tumors, we questioned if the outcome of K14E7 graft
rejection is dependent on IDO activity. In this study we have
identified IDO1 as an immunoregulatory molecule down-
stream of IFN-g and iNKT cells that suppresses immune
responses against HPV16-E7-expressing protein.
RESULTS
IDO inhibition enables rejection of K14E7 skin grafts
To analyze the role of IDO in the rejection of K14E7 grafts, we
administered 1-methyl-dl-tryptophan (1-D/L-MT), an inhibitor
of IDO activity, at 2 mg ml1 in the drinking water of the
K14E7 and C57BL/6 (C57) donor mice and C57 recipient mice
before and after the grafting (Figure 1a). Inhibition of IDO
activity significantly increased rejection of K14E7 grafts but
not C57 control grafts, suggesting that IDO contributes to
suppression of host immune responses against the E7 onco-
protein. K14E7 grafts that were deficient in CD1d expression
(NKT-deficient K14E7 grafts) were used as a positive control
for graft rejection (Figure 1b). We confirmed that administra-
tion of 1-D/L-MT was associated with inhibition of IDO
activity by measuring the serum ratios of kynurenine to
tryptophan concentrations (Figure 1c).
iNKT cells and IFN-c are required for the IDO1 expression in
K14E7 skin
To determine the mechanism by which IDO activity contri-
butes to the suppression of K14E7 graft rejection, we first
analyzed the mRNA expression of IDO1 in transgenic K14E7
skin, and found it significantly higher than in nontransgenic
C57 skin (Figure 2a). IDO2 is another isoform of IDO that could
potentially contribute to an increased kynurenine/tryptophan
ratio and mediates immunosuppression in K14E7 skins (Qian
et al., 2012). However, we observed no difference in IDO2
mRNA expression in K14E7 and control skin (Figure 2b),
suggesting that the increased IDO activity in K14E7 skin is
contributed by IDO1. Consistent with these observations, we
also found significantly higher IDO activity, as determined by
kynurenine/tryptophan ratio, in K14E7 skin than in C57 control
skin (Figure 2c).
TDO is another immunoregulatory enzyme involved in
tryptophan metabolism and may potentially contribute to the
immunosuppressive environment in K14E7 skins (Platten
et al., 2012). However, we did not observe any significant
difference in the mRNA expression of TDO between K14E7
skin and control skin (Figure 2d).
We have recently demonstrated that IFN-g-producing
iNKT cells contribute to suppressive immune effector
mechanisms in E7 transgenic skin (Figure 1b) and protect
K14E7 grafts from rejection (Mattarollo et al., 2010). Elevated
IDO1 mRNA expression, and not IDO2, in K14E7 skin was
not observed if the skin was deficient for IFN-g expression, if
the skin lacked iNKT cells, or if the skin lacked the IFN-g
receptor (IFN-gR; Figure 2e and f). Consistent with the mRNA
data, IDO activity in the skin was also dependent on the
presence of IFN-g and of iNKT cells (Figure 2g). To assess
whether increased IDO activity in K14E7 skin was a local
or a systemic phenomenon, we analyzed IDO activity in the
serum of IFN-g- and iNKT-deficient K14E7 mice. There was
no significant difference in IDO activity in the serum of
K14E7 and nontransgenic C57 mice, suggesting that local
IFN-g in the skin of K14E7 mice contributes to increased
IDO (Figure 2h).
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Figure 1. Inhibition of indoleamine 2,3-dioxygenase (IDO) activity promotes
K14E7 graft rejection. (a) Schematic representation of the administration of
2 mg ml 1 1-methyl-dl-tryptophan (1-D/L-MT) in the drinking water of donor
(C57Bl/6 and K14E7) and recipient C57Bl/6 (C57) mice before and after
grafting. (b) Kaplan–Meier survival curves of C57, K14E7, and K14E7 grafts
deficient in CD1d (CD1d /E7) on immunocompetent C57 recipient mice.
C57 and K14E7 grafts were treated or not with 1-D/L-MT before and after the
grafting. Median graft survival: K14E7þ1-D/L-MT¼ 47 days; C57þ 1-D/L-
MT¼undefined (P¼ 0.02, log-rank test; n¼ 8 mice per group for K14E7 and
C57 grafts; n¼ 4 for CD1d /E7 grafts). (c) IDO activity (kynurenine/
tryptophan (Kyn/Trp)) from the serum of C57 mice transplanted with K14E7
grafts treated or not with 1-D/L-MT for 28 days after grafting.
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DCs in K14E7 skin express elevated level of IFN-cR
As higher levels of IDO1 expression and IDO activity in
K14E7 transgenic skin required IFN-g, we hypothesized that
IDO1 production might be associated with a cell type
expressing higher levels of IFN-gR. We did not observe any
significant difference in the IFN-gR expression between total
K14E7 and C57 skins, and between normal and CIN lesions
(data not shown). However, we observed higher expression of
IFN-gR on DCs (CD45þMHCIIþCD11cþ ) from K14E7 skin
than DCs from C57 control skin, whereas expression of IFN-gR
in non-DCs (CD45þMHCIICD11c ) and CD45-negative
nonhematopoietic population was not significantly different
between K14E7 and control skin (Figure 3a and b).
Interestingly, the higher expression of IFN-gR on K14E7 skin
DCs was independent of production of IFN-g in the skin
(Figure 3a and b). Together, these results suggest that IFN-
gRþ DCs in K14E7 skin may be the source of IDO1 and
contribute to the suppression of K14E7 graft rejection.
CD11cþ DCs in K14E7 skins express IDO
We next tested if DCs in K14E7 skin are the main cells
expressing IDO1. Flow cytometry staining on CD45þ
CD11cþ DCs in K14E7 skin demonstrated IDO1 expression
in CD11cþ DCs but not on the CD3þ lymphocyte population
(Figure 4a and b). In contrast, DCs from nontransgenic C57
skin expressed little or no IDO1. In addition, we observed
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Figure 2. Indoleamine 2,3-dioxygenase (IDO1) expression in K14E7 skin is dependent on IFN-c and invariant natural killer T (iNKT) cells. Expression of
mRNA for (a) IDO1, (b) IDO2, and (d) tryptophan 2,3-dioxygenase (TDO) relative to RPL32 (L32) determined by real-time PCR in the ear skin of K14E7 and
nontransgenic C57 mice. (c) IDO activity as measured by HPLC from the ear skin lysates of K14E7 and C57 mice. (n¼10 for K14E7; n¼ 7 for C57.) Expression of
mRNA for (e) IDO1 and (f) IDO2 relative to L32 by real-time PCR in the ear skin of C57, K14E7, and K14E7 mice deficient in Ja18 (Ja18 /E7), CD1d
(CD1d /E7), IFN-g (IFN-g /E7), or IFN-g receptor (IFN-gR /E7). IDO activity as measured by HPLC from (g) ear skin lysates and (h) serum of C57, K14E7,
Ja18 /E7, CD1d /E7, IFN-g /E7, and IFN-gR /E7. Kyn/Trp, kynurenine/tryptophan; NS, not significant. n¼ 14 for K14E7 and n¼ 10 for C57; nX4
for other mice.
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Figure 3. Skin dendritic cells (DCs) in K14E7 mice express high levels of IFN-cR. (a) Histogram plots showing flow cytometry staining for surface IFN-g receptor
(IFN-gR; unfilled black histograms) and isotype controls (filled gray histograms) in the ear skin of C57 (top), K14E7 (middle), and IFN-g /E7 (bottom) mice. (b) Bar
graph shows surface levels of IFN-gR expression on DCs from ear skin of C57 (white), K14E7 (black), and IFN-g /E7 (gray) mice shown as dMFI (mean
fluorescence intensity; dMFI¼MFI of IFN-gR mAbMFI of isotype control mAb). IFNgR /E7 mice (line bar) were used as a negative control for IFNgR staining.
Meanþ SEM; n¼4 mice per group for K14E7 and IFN-g /E7; n¼ 6 for C57 mice, data pooled from two independent experiments.
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Figure 4. Dendritic cell (DC) infiltrates in K14E7 skin express indoleamine 2,3-dioxygenase 1 (IDO1) that is dependent on IFN-cR on DCs. (a) Flow cytometry
plot showing CD3 and CD11c staining (left) on the skin cells pregated on CD45þ live cells. Histogram plot showing intracellular staining for IDO1 (filled black
histogram) and isotype controls (filled gray histogram) in CD3þ lymphocytes and CD11cþ cells from K14E7, C57, and IFN-gR /E7 mice. (b) Bar graph
shows representative FACS data as the percentage of IDO1-positive DCs in the skin of C57, K14E7, and IFN-gR /E7 mice. Meanþ SEM; n¼ 4 mice per group for
K14E7 and IFN-g /E7; n¼6 for C57 mice. (c) FACS plot showing gating strategy for sorting resident (CD11cþMHCint) and migratory (CD11cþMHChi) DCs.
MHC, major histocompatibility complex. (d) mRNA expression of IDO1 relative to RPL32 by real-time PCR in the resident (res) and migratory (mig) DCs
sorted from the skin-draining lymph nodes of K14E7 mice. ND, not detectable. (e) Bar graph shows absolute number of MHCIIþCD11cþ DCs (representative of
FACS data) in the ear skin of C57, K14E7, IFN-g /E7, and IFN-gR /E7 mice.
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reduced IDO1 expression in the skin DCs from IFN-gR-
deficient K14E7 mice (Figure 4a and b), confirming that
IFN-gR signaling induces increased expression of IDO1 in
K14E7 skin DCs. We further show with immunofluorescence
staining that IDO1 is expressed by DCs in the dermis of K14E7
mice and injection of IFN-g induces IDO1 expression in both
CD11cþ and CD11c cells in IFN-g-deficient K14E7 mice
(Supplementary Figure S1a and b online).
To further confirm that IDO1 expression by skin DCs is due
to local signaling, we isolated migratory (CD11cþMHCIIhigh)
and resident DCs (CD11cþMHCIIintermediate) from the skin-
draining lymph nodes of K14E7 mice (Figure 4c). Resident
DCs did not express any detectable IDO1 in contrast to high
levels of expression in migratory DCs, suggesting that local
IFN-g in the K14E7 skin induces IDO1 expression (Figure 4d).
In addition, we observed a higher proportion of MHCIIþ
CD11cþ DCs in K14E7 skin than in C57 skin, and the
increased number of DCs in the K14E7 skin was independent
of IFN-g or IFN-gR expression (Figure 4e). This result suggests
that the previously demonstrated rejection of IFN-g /
E7 (Mattarollo et al., 2010) and IFN-gR /E7 skin grafts
(R Kluyver, PhD thesis, 2008) is not attributable to the
difference in DC recruitment to the skin.
Langerin ve dermal DCs express IDO1 and contribute to
increased DC infiltrates in K14E7 skin
In skin, several DC subsets have been identified (Henri et al.,
2010). In K14E7 skin, we found that langerin ve dermal DCs
are the main contributors to increased DC numbers
(Figure 5a–d). Furthermore, IDO1 expression in the skin of
K14E7 mice was restricted to langerin ve DCs (Figure 5e and
f). In addition to strengthening the relation of IFN-g induced
IDO1 in immune suppression, we show that splenic DCs from
K14E7 mice, when prestimulated with IFN-g, could induce
IDO1 expression (Supplementary Figure S2 online) and also
suppress CD8 cell proliferation (Figure 5g).
IDO expression in CIN patients
Having established that local IDO activity in K14E7 transgenic
mouse skin is necessary to protect K14E7 skin from immune-
mediated rejection, we examined the expression of IDO1,
IDO2, and other related genes in HPV-associated CIN-2/3
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Figure 5. Indoleamine 2,3-dioxygenase 1 (IDO1) is expressed by langerin ve dendritic cells (DCs). (a) Dot plot shows classical dermal DCs (CD11bþCD207 ),
Langerhans cells (CD207þCD103 ), and CD207þCD103þ DCs in the skin of K14E7 mice gated on live CD45þCD11cþMHCIIþ cells. MHC, major
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K14E7 mice (meanþ SEM; n¼ 4 mice per group for K14E7 and n¼6 for C57 mice). (e) Isotype control and (f) real staining for IDO1 and CD207, pregated on
CD11cþMHCIIþ cells, in the ear skin of K14E7 mice. (g) Proliferation of splenic CD8 cells cultured with splenic DCs (DC/T/irradiated feeder cells 1:5:5)
from K14E7 and IFN-gR /E7 mice with or without 1-MT (1 mM) and IFN-g (10 ng ml1). Results are expressed as mean counts per minute (c.p.m.)±SEM of
triplicate wells.
D Mittal et al.
Role of IDO in the Immune Suppression of HPV
2690 Journal of Investigative Dermatology (2013), Volume 133
patients and surrounding cervical epithelial tissues. Consistent
with previous studies (Kobayashi et al., 2008), we found
higher mRNA expression of IDO1 and IFN-g, but not of
IDO2, in CIN-2/3 cervical biopsy samples (Figure 6).
DISCUSSION
We have previously shown that skin expressing HPV16 E7
oncoprotein is hyperplastic and has increased immune cell
infiltrate, relative to skin from syngeneic nontransgenic mice.
Immunization along with adoptive transfer of high numbers of
E7-specific CD8 T cells is required to successfully reject
K14E7 skin grafts (Matsumoto et al., 2004). This generates
circulating memory T cells. However, they fail to reject
second newly placed K14E7 grafts and a further
immunization is required (Matsumoto et al., 2004),
suggesting that the expression of E7 oncoprotein generates a
potent local immunosuppressive environment in the host.
Understanding the mechanisms that lead to successful
rejection of K14E7 grafts could pave the way for future
immunotherapies against HPV-associated cancers.
We have recently shown that iNKT cells are specifically
attracted to hyperplastic K14E7 skin, and IFN-g production by
iNKT cells is critical for the protection of K14E7 grafts
(Mattarollo et al., 2010). We hypothesized that IFN-g
induces immunoregulatory molecules such as IDO1 that is
required for the survival of K14E7 grafts on immunocompetent
host. In this study we demonstrate that inhibition of IDO
activity by 1-D/L-MT successfully rejects K14E7 grafts. We
used a mixture of D- and L- stereoisomer of 1-MT that is known
to inhibit both IDO1 and IDO2. However, we have shown
that it is mainly IDO1 and not IDO2 that is overexpressed in
K14E7 skins and CIN lesions. This is consistent with previous
observations where increased IDO1 has been associated with
skin lesions of inflammatory skin disease (Ito et al., 2004).
Moreover, IDO1 expression and IDO activity is dependent on
IFN-g and iNKT cells as K14E7 skin deficient in CD1d, Ja18,
IFN-g, or IFN-gR had IDO1 expression and IDO activity
similar to nontransgenic controls (Figure 2e–h). We also
observed a transient increase in IDO1 expression at day 3
after grafting that was dependent on IFN-g expression in the
K14E7 grafted skin (data not shown). Our data agree with
recent studies showing that iNKT ligand a-galactosylceramide
induces IDO1 possibly by releasing IFN-g (Fallarini et al.,
2008; Guillonneau et al., 2009).
TDO is another enzyme of tryptophan metabolism that can
potentially contribute to observed local kynurenine concen-
tration in K14E7 skins (Platten et al., 2012). However, we
did not detect any significant difference in TDO expres-
sion between K14E7 and nontransgenic control skins,
demonstrating that increased IDO1 in K14E7 skin
contributes to increased kynurenine production that is likely
to be related to observed immunosuppression. We could
obtain K14E7 graft rejection in only half of the transplanted
grafts. This partial but significant rejection can be explained by
incomplete inhibition of IDO by 1-D/L-MT. Indeed, we found
that graft rejection was correlated to the inhibition of IDO
activity. Alternatively, other redundant immunoregulatory
compensatory mechanisms, including IFN-g-inducible mole-
cules such as PD-L1/2 (programmed cell death 1 ligand 1/2)
(or Tim-3 (T cell Ig and mucin-domain 3) that may act alone
or in association with IDO1 as has been proposed recently
(Sharma et al., 2007; Baban et al., 2011), may be induced
upon inhibition of IDO activity.
DCs are specialized cell types that acquire process and
present antigens to T cells, leading to their activation, clonal
expansion, and differentiation into effector T cells. However,
some DCs suppress T-cell responses by generating T cells with
regulatory functions, including CD4þCD25þFoxp3þ regula-
tory T cells (Tregs) (Huang et al., 2010). IDO1 expression by
DCs and plasmacytoid DCs has been shown to induce
immune tolerance that is related to the pathogenesis of
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Figure 6. Elevated indoleamine 2,3-dioxygenase 1 (IDO1) and IFN-c mRNA
expression in cervical intraepithelial neoplasia (CIN) lesions. (a) mRNA
expression of human IDO1, (b) IDO2, and (c) IFN-g relative to HPRT by
real-time PCR in biopsies of normal (NT) cervical epithelium and CIN 2/3 (CIN)
tissue. Meanþ SEM; n¼7. IDO2 expression was not detectable in most
of the samples analyzed.
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chronic hepatitis C infection (Higashitani et al., 2012),
suppression of antitumor immune responses (Munn et al.,
2004; Sharma et al., 2007), and collagen-induced arthritis
(Park et al., 2012). DC-SIGN (DC-Specific Intercellular
adhesion molecule-3-Grabbing Non-integrin) expressing
CD1aþ immature DCs in the stroma of high-grade CIN
lesions express immunosuppressive factors such as IDO1,
tumor growth factor b, and IL-10 (Kobayashi et al., 2008).
However, in K14E7 skin, IDO1 expression was restricted to
langerin ve DCs (Figure 5e and f). We predict that, similar
to iNKT cells, DCs are specifically recruited to K14E7 hyper-
plastic skin. DC recruitment to the hyperplastic skin is
independent of IFN-g or IFN-gR expression (Figure 4e). It is
likely that after reaching the skin, these cells produce high
levels of IDO1 because of the presence of high quantity of
local IFN-g, as K14E7 skin DCs deficient for IFN-gR did not
have IDO1 expression (Figure 4a and b). In support of this
hypothesis, we observed that unlike migratory DCs, resident
DCs did not express IDO1 in the skin-draining lymph nodes of
K14E7 mice. This is consistent with the recent literature that
high level of IFN-g is anti-inflammatory (Minguela et al., 2007).
The mechanism that IDO1 uses to induce immunosuppres-
sion includes generation of Tregs. IDO1 expressing DCs
activate FoxP3þ Tregs that are a major regulatory cell
population for suppressing effector responses (Huang et al.,
2010; Higashitani et al., 2012). However, Tregs are not
involved in IDO1-mediated immune resistance in K14E7
skin, as we have shown previously that, although high in
number in K14E7 skins, depletion of FoxP3þ Tregs did not
elicit graft rejection (Mattarollo et al., 2011). IDO enzymatic
activity can directly suppress effector responses by depletion
of tryptophan, by production of tryptophan metabolites
(kynurenines), and by changing redox potentials due to
consumption of superoxide radicals (reviewed in Huang
et al., 2010). T cells are highly sensitive to changes in local
tryptophan concentrations, and kynurenines can induce
proliferative arrest and apoptosis in T cells that is dependent
on GCN-2 (general control nonrepressed 2) kinase (Fallarino
et al., 2006). Therefore, we hypothesize that in the model of
K14E7 skin grafting, increased kynurenine and decreased
tryptophan concentrations inhibit effector T-cell functions
and suppress graft rejection.
Overall, our data strongly suggest a critical immune
regulatory role of IDO1 in K14E7 hyperplastic skin. In this
model, the potent immunosuppressive IDO1 expression in
DCs is induced by local IFN-g produced from iNKT cells in
the skin. Consistent with previous studies (Kobayashi et al.,
2008), we also observed elevated mRNA expression of IFN-g
and IDO1 in CIN-2/3 samples than in normal tissue.
Collectively, our observations support the use of 1-MT for
immunotherapy against HPV-associated epithelial cancers.
MATERIALS AND METHODS
Mice
C57BL/6 mice and HPV16-E7 transgenic mice, in which E7 onco-
protein is expressed in basal keratinocytes under the control of K14
promoter (designated K14E7), were obtained from the Animal
Resources Center (Perth, Australia). IFN-g / and IFN-gR / mice
were purchased from The Jackson Laboratory (Bar Harbor, ME) and
NKT cell–deficient CD1d / and Ja18 / mice were obtained
from M Smyth (Melbourne, Australia). To generate K14E7 transgenic
crosses with CD1d / , Ja18 / , IFN-g / , and IFN-gR /
knockout mice, hemizygous K14E7 mice were crossed and then
backcrossed with homozygous CD1d / , Ja18 / , IFN-g / , or
IFN-gR / mice to an F2 generation. All mice were on C57Bl/6
background and K14E7-negative littermate controls were used for
several experiments. All mice were housed under specific pathogen-
free conditions at the Princess Alexandra Hospital Biological
Research Facility (Brisbane, Australia), and were sex matched and
used at 6–10 weeks of age for all experiments. All animal procedures
were approved by the University of Queensland Animal Ethics
Committee.
Skin transplantation
Skin from donor mice was transplanted onto the flank of recipient
mice as previously described (Dunn et al., 1997; Matsumoto et al.,
2004). Briefly, donor skin was taken from the dorsal and ventral
surfaces of the ear (B1 cm2) and placed onto the thoracic flank region
of anesthetized recipients. Grafts were held in place with antibiotic-
permeated gauze (Bactigras; Smith and Nephew, London, UK) and
bandaged with micropore tape and Flex-wrap (Lyppard, Queensland,
Australia). Bandages were removed 7 days after grafting, and grafts
were monitored daily for loss of distinct border and signs of ulceration
or necrosis to 480% of the graft, which was used to define graft
rejection.
Inhibition of IDO with 1-D/L-MT
The 1-D/L-MT was obtained from Sigma-Aldrich (St Louis, MO) and
prepared as a 20 mmol l 1 stock in 0.1 N NaOH, adjusted to pH 7.4,
and stored at 4 1C protected from light. Mice were given 2 mg ml 1 of
1-D/L-MT in the drinking water, supplemented with 2 g l 1 of
aspartame (Equal), before and after grafting as shown in Figure 1a.
Mice drank an average of 5 ml per day and water was replaced every
5 days during the grafting. Mice administrated with 1-D/L-MT in the
drinking water did not show change in weight and the amount of
water intake was similar to control groups.
Immunofluorescence
Excised ear skin samples were fixed in PLP buffer, dehydrated in 20%
sucrose, and stained with fluorochrome-conjugated antibodies as
described previously (Mittal et al., 2010).
Quantitative real-time PCR
Mouse ear samples were homogenized in trizol and RNA was
extracted using a RNeasy kit (Qiagen, Chadstone, Victoria, Australia).
All human subjects provided written informed consent and the
experiments were approved by the institution ethics committee
(2009001060) and conducted in compliance with the Declaration
of Helsinki Principles.
HPLC
Serum and ear skin tissues from mice were collected and analyzed for
kynurenine and tryptophan concentrations (mM) on HPLC (Agilent
Technologies Series 1,200, Mulgrave, Victoria, Australia) as described
previously (Laich et al., 2002). In brief, tissues were homogenized
in phosphate-buffered saline containing protease inhibitors (Roche
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Applied Sciences, Indianapolis, IN). Tissue supernatants and serum
were deproteinated in TCA and 50ml was used for HPLC (C18
reverse-phase column). Peak area values for kynurenine and
tryptophan were determined and the results for IDO activity were
plotted as a kynurenine/tryptophan ratio.
Flow cytometry
Flow cytometry staining was performed as previously described
(Mattarollo et al., 2010).
T-cell stimulation assay
DCs were purified by CD11cþ -positive selection and splenic CD8þ
cells were stained with anti-CD8 phycoerythrin. Anti-phycoerythrin
beads (Miltenyi Biotech, Macquarie Park, NSW, Australia) were used
to purify the cells (magnetic cell sorter (MACS), Miltenyi Biotech).
Purified DCs from spleen of K14E7 mice were incubated with splenic
CD8 (2 105 cells per well) from K14E7 mice (DC/T cell 1:10) in the
presence of irradiated splenocytes in RPMI complete medium for
4 days in a 96-well U-bottom plate. For some experiments, purified
splenic DCs from K14E7- and IFN-gR-deficient K14E7 mice were
preincubated with recombinant mouse IFN-g (R&D Systems, USA) for
24 hours before culturing with T cells. The cultures were then pulsed
with 1mCi [3H]-thymidine for 18 hours and the radioactivity incorpo-
rated was determined with a Beta Scintillation Counter (Microbeta
Trilux, Perkin Elmer, Wellesley, MA).
Statistical analysis
Kaplan–Meier plots were used to analyze skin graft survival, and a
log-rank test was performed to assess the statistical significance of
differences between survival curves. For human CIN samples, a two-
tailed paired nonparametric Wilcoxon test was performed. For all
other data in which statistics were performed, a two-tailed, nonpara-
metric Mann–Whitney test was used for assessment of differences
between groups. All experiments were repeated two to three times
with similar results. Differences with a P-value of o0.05 were
considered to be significant. Prism (Graph pad Software, La Jolla,
CA) was used for graphs and statistical analysis.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by grants from the NIH (5U01CA141583), National
Health and Medical Research Council of Australia (569938), Australian
Research Council, and the Cancer Council Queensland, also ACRF. We thank
Lewis Perrin from Mater Medical Centre, Brisbane, for providing human CIN
and normal tissues, Ranjeny Thomas’ group for technical assistance with
HPLC, and the staff of the Biological Research Facility at Princess Alexandra
Hospital for excellent technical assistance with grafting and animal care.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Baban B, Chandler PR, Johnson BA 3rd et al. (2011) Physiologic control of IDO
competence in splenic dendritic cells. J Immunol 187:2329–35
Bhat P, Mattarollo SR, Gosmann C et al. (2011) Regulation of immune
responses to HPV infection and during HPV-directed immunotherapy.
Immunol Rev 239:85–98
Dunn LA, Evander M, Tindle RW et al. (1997) Presentation of the HPV16E7
protein by skin grafts is insufficient to allow graft rejection in an E7-
primed animal. Virology 235:94–103
Fallarini S, Paoletti T, Panza L et al. (2008) Alpha-galactosylceramide
modulates the induction of indoleamine 2,3-dioxygenase in antigen
presenting cells. Biochem Pharmacol 76:738–50
Fallarino F, Grohmann U, You S et al. (2006) The combined effects of
tryptophan starvation and tryptophan catabolites down-regulate T cell
receptor zeta-chain and induce a regulatory phenotype in naive T cells.
J Immunol 176:6752–61
Godin-Ethier J, Hanafi LA, Piccirillo CA et al. (2011) Indoleamine 2,3-
dioxygenase expression in human cancers: clinical and immunologic
perspectives. Clin Cancer Res 17:6985–91
Guillonneau C, Mintern JD, Hubert FX et al. (2009) Combined
NKT cell activation and influenza virus vaccination boosts
memory CTL generation and protective immunity. Proc Natl Acad Sci
USA 106:3330–5
Henri S, Guilliams M, Poulin LF et al. (2010) Disentangling the complexity of
the skin dendritic cell network. Immunol Cell Biol 88:366–75
Higashitani K, Kanto T, Kuroda S et al. (2012) Association of enhanced activity
of indoleamine 2,3-dioxygenase in dendritic cells with the induction
of regulatory T cells in chronic hepatitis C infection. J Gastroenterol
48:660–70
Huang L, Baban B, Johnson BA 3rd et al. (2010) Dendritic cells, indoleamine
2,3 dioxygenase and acquired immune privilege. Int Rev Immunol
29:133–55
Huang TT, Yen MC, Lin CC et al. (2011) Skin delivery of short hairpin RNA of
indoleamine 2,3 dioxygenase induces antitumor immunity against ortho-
topic and metastatic liver cancer. Cancer Sci 102:2214–20
Ito M, Ogawa K, Takeuchi K et al. (2004) Gene expression of enzymes
for tryptophan degradation pathway is upregulated in the skin
lesions of patients with atopic dermatitis or psoriasis. J Dermatol Sci
36:157–64
Kobayashi A, Weinberg V, Darragh T et al. (2008) Evolving immuno-
suppressive microenvironment during human cervical carcinogenesis.
Mucosal Immunol 1:412–20
Laich A, Neurauter G, Widner B et al. (2002) More rapid method for
simultaneous measurement of tryptophan and kynurenine by HPLC. Clin
Chem 48:579–81
Lob S, Konigsrainer A, Zieker D et al. (2009) IDO1 and IDO2 are expressed in
human tumors: levo- but not dextro-1-methyl tryptophan inhibits trypto-
phan catabolism. Cancer Immunol Immunother 58:153–7
Matsumoto K, Leggatt GR, Zhong J et al. (2004) Impaired antigen presentation
and effectiveness of combined active/passive immunotherapy for epithe-
lial tumors. J Natl Cancer Inst 96:1611–9
Mattarollo SR, Rahimpour A, Choyce A et al. (2010) Invariant NKT cells in
hyperplastic skin induce a local immune suppressive environment by IFN-
gamma production. J Immunol 184:1242–50
Mattarollo SR, Yong M, Gosmann C et al. (2011) NKT cells inhibit antigen-
specific effector CD8 T cell induction to skin viral proteins. J Immunol
187:1601–8
Metz R, Duhadaway JB, Kamasani U et al. (2007) Novel tryptophan catabolic
enzyme IDO2 is the preferred biochemical target of the antitumor
indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-trypto-
phan. Cancer Res 67:7082–7
Minguela A, Pastor S, Mi W et al. (2007) Feedback regulation of murine
autoimmunity via dominant anti-inflammatory effects of interferon
gamma. J Immunol 178:134–44
Mittal D, Saccheri F, Venereau E et al. (2010) TLR4-mediated skin car-
cinogenesis is dependent on immune and radioresistant cells. EMBO J
29:2242–52
Muller AJ, Sharma MD, Chandler PR et al. (2008) Chronic inflammation
that facilitates tumor progression creates local immune suppression by
inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 105:
17073–8
Munn DH, Mellor AL (2012) Indoleamine 2,3 dioxygenase and metabolic
control of immune responses. Trends Immunol 34:137–43
D Mittal et al.
Role of IDO in the Immune Suppression of HPV
www.jidonline.org 2693
Munn DH, Sharma MD, Hou D et al. (2004) Expression of indoleamine 2,3-
dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph
nodes. J Clin Invest 114:280–90
Nowak EC, de Vries VC, Wasiuk A et al. (2012) Tryptophan hydroxylase-1
regulates immune tolerance and inflammation. J Exp Med 209:2127–35
Orabona C, Grohmann U (2011) Indoleamine 2,3-dioxygenase and
regulatory function: tryptophan starvation and beyond. Methods Mol Biol
677:269–80
Pardoll DM (2012) The blockade of immune checkpoints in cancer immuno-
therapy. Nat Rev Cancer 12:252–64
Park MJ, Park KS, Park HS et al. (2012) A distinct tolerogenic subset of splenic
IDO(þ )CD11b(þ ) dendritic cells from orally tolerized mice is respon-
sible for induction of systemic immune tolerance and suppression of
collagen-induced arthritis. Cell Immunol 278:45–54
Platten M, Wick W, Van den Eynde BJ (2012) Tryptophan catabolism in
cancer: beyond IDO and tryptophan depletion. Cancer Res 72:5435–40
Qian F, Liao J, Villella J et al. (2012) Effects of 1-methyltryptophan stereo-
isomers on IDO2 enzyme activity and IDO2-mediated arrest of human
T cell proliferation. Cancer Immunol Immunother 61:2013–20
Sharma MD, Baban B, Chandler P et al. (2007) Plasmacytoid dendritic cells
from mouse tumor-draining lymph nodes directly activate mature Tregs
via indoleamine 2,3-dioxygenase. J Clin Invest 117:2570–82
Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol
19:217–23
Yen MC, Lin CC, Chen YL et al. (2009) A novel cancer therapy by skin delivery
of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 15:641–9
zur Hausen H, de Villiers EM, Gissmann L (1981) Papillomavirus infections
and human genital cancer. Gynecol Oncol 12(2 Pt 2):S124–8
D Mittal et al.
Role of IDO in the Immune Suppression of HPV
2694 Journal of Investigative Dermatology (2013), Volume 133
